JP2019151657A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019151657A5 JP2019151657A5 JP2019093861A JP2019093861A JP2019151657A5 JP 2019151657 A5 JP2019151657 A5 JP 2019151657A5 JP 2019093861 A JP2019093861 A JP 2019093861A JP 2019093861 A JP2019093861 A JP 2019093861A JP 2019151657 A5 JP2019151657 A5 JP 2019151657A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- content
- irbesartan
- amlodipine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 12
- 239000002947 C09CA04 - Irbesartan Substances 0.000 claims 3
- YCPOHTHPUREGFM-UHFFFAOYSA-N Irbesartan Chemical compound O=C1N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C=2[N]N=NN=2)C(CCCC)=NC21CCCC2 YCPOHTHPUREGFM-UHFFFAOYSA-N 0.000 claims 3
- 229960002198 irbesartan Drugs 0.000 claims 3
- VUKAUDKDFVSVFT-UHFFFAOYSA-N 2-[6-[4,5-bis(2-hydroxypropoxy)-2-(2-hydroxypropoxymethyl)-6-methoxyoxan-3-yl]oxy-4,5-dimethoxy-2-(methoxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)-5-methoxyoxane-3,4-diol Chemical compound COC1C(OC)C(OC2C(C(O)C(OC)C(CO)O2)O)C(COC)OC1OC1C(COCC(C)O)OC(OC)C(OCC(C)O)C1OCC(C)O VUKAUDKDFVSVFT-UHFFFAOYSA-N 0.000 claims 2
- HTIQEAQVCYTUBX-UHFFFAOYSA-N Amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 claims 2
- JEIPFZHSYJVQDO-UHFFFAOYSA-N Iron(III) oxide Chemical compound O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 claims 2
- 229960000528 amlodipine Drugs 0.000 claims 2
- 239000011230 binding agent Substances 0.000 claims 2
- 239000011248 coating agent Substances 0.000 claims 2
- 239000003086 colorant Substances 0.000 claims 2
- 239000007884 disintegrant Substances 0.000 claims 2
- 239000007888 film coating Substances 0.000 claims 2
- 238000009501 film coating Methods 0.000 claims 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 2
- 229910000460 iron oxide Inorganic materials 0.000 claims 2
- 239000010410 layer Substances 0.000 claims 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims 2
- 239000004014 plasticizer Substances 0.000 claims 2
- DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Chemical group CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 239000011780 sodium chloride Substances 0.000 claims 2
- 229960001681 Croscarmellose Sodium Drugs 0.000 claims 1
- 229920002785 Croscarmellose sodium Polymers 0.000 claims 1
- FBPFZTCFMRRESA-KAZBKCHUSA-N D-Mannitol Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KAZBKCHUSA-N 0.000 claims 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims 1
- 229940031703 LOW SUBSTITUTED HYDROXYPROPYL CELLULOSE Drugs 0.000 claims 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 1
- XAPRFLSJBSXESP-UHFFFAOYSA-N Oxycinchophen Chemical compound N=1C2=CC=CC=C2C(C(=O)O)=C(O)C=1C1=CC=CC=C1 XAPRFLSJBSXESP-UHFFFAOYSA-N 0.000 claims 1
- 239000004372 Polyvinyl alcohol Substances 0.000 claims 1
- OGIDPMRJRNCKJF-UHFFFAOYSA-N TiO Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 claims 1
- 239000001913 cellulose Substances 0.000 claims 1
- 229920002678 cellulose Polymers 0.000 claims 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims 1
- 229940071676 hydroxypropylcellulose Drugs 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 239000000314 lubricant Substances 0.000 claims 1
- 235000019359 magnesium stearate Nutrition 0.000 claims 1
- 235000010355 mannitol Nutrition 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 claims 1
- 229920002451 polyvinyl alcohol Polymers 0.000 claims 1
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 claims 1
- 229910001929 titanium oxide Inorganic materials 0.000 claims 1
Claims (11)
(b)Ｄ-マンニトール及び結晶セルロースからなる賦形剤、並びに
(c)ヒドロキシプロピルメチルセルロース、ヒドロキシプロピルセルロース及びポリビニルアルコールからなる群から選ばれる１種又は２種以上からなる結合剤、
を含有する医薬組成物であって、
(d)アムロジピンまたはその塩、及び、(e)クロスカルメロースナトリウム及び／又は低置換度ヒドロキシプロピルセルロースからなる崩壊剤をさらに含み、
前記イルベサルタンの含量が４８．８ｗ／ｗ％〜６５ｗ／ｗ％であり、前記アムロジピンまたはその塩の含量が１ｗ／ｗ％〜１０ｗ／ｗ％であることを特徴とする、医薬組成物。 (a) Irbesartan,
(b) an excipient comprising D-mannitol and crystalline cellulose , and
(c) a binder consisting of one or more selected from the group consisting of hydroxypropylmethylcellulose, hydroxypropylcellulose and polyvinyl alcohol ,
A pharmaceutical composition comprising:
(d) further comprising a disintegrant comprising amlodipine or a salt thereof, and (e) croscarmellose sodium and / or low-substituted hydroxypropylcellulose,
A pharmaceutical composition, wherein the content of irbesartan is 48.8 w / w% to 65 w / w%, and the content of amlodipine or a salt thereof is 1 w / w% to 10 w / w% .
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021070089A JP2021152003A (en) | 2011-09-13 | 2021-04-19 | Method for stabilizing pharmaceutical composition containing irbesartan and amlodipine or salt thereof |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2011199987 | 2011-09-13 | ||
| JP2011199987 | 2011-09-13 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018171042A Division JP6530845B2 (en) | 2011-09-13 | 2018-09-13 | Method of Stabilizing a Pharmaceutical Composition Comprising Irbesartan and Amlodipine or a Salt Thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021070089A Division JP2021152003A (en) | 2011-09-13 | 2021-04-19 | Method for stabilizing pharmaceutical composition containing irbesartan and amlodipine or salt thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019151657A JP2019151657A (en) | 2019-09-12 |
| JP2019151657A5 true JP2019151657A5 (en) | 2019-12-05 |
Family
ID=48479652
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012201332A Active JP6041591B2 (en) | 2011-09-13 | 2012-09-13 | Stabilized pharmaceutical composition comprising irbesartan and amlodipine or a salt thereof |
| JP2016218298A Active JP6404886B2 (en) | 2011-09-13 | 2016-11-08 | Method for stabilizing pharmaceutical compositions containing irbesartan and amlodipine or a salt thereof |
| JP2018171042A Active JP6530845B2 (en) | 2011-09-13 | 2018-09-13 | Method of Stabilizing a Pharmaceutical Composition Comprising Irbesartan and Amlodipine or a Salt Thereof |
| JP2019093861A Pending JP2019151657A (en) | 2011-09-13 | 2019-05-17 | Method for stabilizing pharmaceutical composition containing irbesartan and amlodipine or salt thereof |
| JP2021070089A Pending JP2021152003A (en) | 2011-09-13 | 2021-04-19 | Method for stabilizing pharmaceutical composition containing irbesartan and amlodipine or salt thereof |
Family Applications Before (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012201332A Active JP6041591B2 (en) | 2011-09-13 | 2012-09-13 | Stabilized pharmaceutical composition comprising irbesartan and amlodipine or a salt thereof |
| JP2016218298A Active JP6404886B2 (en) | 2011-09-13 | 2016-11-08 | Method for stabilizing pharmaceutical compositions containing irbesartan and amlodipine or a salt thereof |
| JP2018171042A Active JP6530845B2 (en) | 2011-09-13 | 2018-09-13 | Method of Stabilizing a Pharmaceutical Composition Comprising Irbesartan and Amlodipine or a Salt Thereof |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021070089A Pending JP2021152003A (en) | 2011-09-13 | 2021-04-19 | Method for stabilizing pharmaceutical composition containing irbesartan and amlodipine or salt thereof |
Country Status (1)
| Country | Link |
|---|---|
| JP (5) | JP6041591B2 (en) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6041591B2 (en) * | 2011-09-13 | 2016-12-14 | 大日本住友製薬株式会社 | Stabilized pharmaceutical composition comprising irbesartan and amlodipine or a salt thereof |
| JP6238921B2 (en) * | 2014-02-17 | 2017-11-29 | 大原薬品工業株式会社 | Tablets containing irbesartan |
| JP6199922B2 (en) * | 2015-03-20 | 2017-09-20 | 大原薬品工業株式会社 | Irbesartan-containing tablets with improved chemical stability |
| CN105412029A (en) * | 2015-12-03 | 2016-03-23 | 南京多宝生物科技有限公司 | Anti-hypertension benzene sulfonic acid levamlodipine besylate tablet |
| JP6321131B2 (en) * | 2016-02-12 | 2018-05-09 | 大原薬品工業株式会社 | Dissolution improvement method of amlodipine-containing combination tablets |
| JP2017210435A (en) * | 2016-05-25 | 2017-11-30 | ダイト株式会社 | Method for producing irbesartan and amlodipine besylate-containing tablet |
| JP6233911B2 (en) * | 2017-08-22 | 2017-11-22 | 大原薬品工業株式会社 | Irbesartan-containing tablets with improved chemical stability |
| JP2018009032A (en) * | 2017-10-19 | 2018-01-18 | 大原薬品工業株式会社 | Tablet containing irbesartan with improved chemical stability |
| CN112022817B (en) * | 2020-08-04 | 2022-08-26 | 河北君临药业有限公司 | Nifedipine tablet composition and preparation method thereof |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9408117D0 (en) * | 1994-04-23 | 1994-06-15 | Smithkline Beecham Corp | Pharmaceutical formulations |
| CN101068546A (en) * | 2004-10-06 | 2007-11-07 | 卫材R&D管理有限公司 | Medicinal composition, process for producing the same, and method of stabilizing dihydropyridine compound in medicinal composition |
| US20100016378A1 (en) * | 2005-04-28 | 2010-01-21 | Toshio Suzuki | Method of preventing dihydropyridine compound from degradation |
| JP5110697B2 (en) * | 2005-06-27 | 2012-12-26 | 第一三共株式会社 | Solid preparation |
| WO2009084003A1 (en) * | 2007-12-31 | 2009-07-09 | Lupin Limited | Pharmaceutical compositions of amlodipine and valsartan |
| JP2009196940A (en) * | 2008-02-22 | 2009-09-03 | Takada Seiyaku Kk | Tablet quickly disintegrating in oral cavity and its production method |
| EP2285352A2 (en) * | 2008-05-13 | 2011-02-23 | Dr. Reddy's Laboratories Ltd. | Atorvastatin compositions |
| JP5296456B2 (en) * | 2008-08-26 | 2013-09-25 | 大日本住友製薬株式会社 | Irbesartan-containing pharmaceutical composition with good dissolution and orally disintegrating tablet |
| NZ594738A (en) * | 2009-01-23 | 2013-11-29 | Hanmi Science Co Ltd | Solid pharmaceutical composition comprising amlodipine and losartan and process for producing same |
| CA2766884C (en) * | 2009-06-30 | 2016-08-23 | Sanofi | Solid pharmaceutical fixed dose compositions comprising irbesartan and amlodipine, their preparation and their therapeutic application |
| JP5421945B2 (en) * | 2010-03-10 | 2014-02-19 | 大日本住友製薬株式会社 | Pharmaceutical composition containing irbesartan and amlodipine or a salt thereof |
| JP6041591B2 (en) * | 2011-09-13 | 2016-12-14 | 大日本住友製薬株式会社 | Stabilized pharmaceutical composition comprising irbesartan and amlodipine or a salt thereof |
-
2012
- 2012-09-13 JP JP2012201332A patent/JP6041591B2/en active Active
-
2016
- 2016-11-08 JP JP2016218298A patent/JP6404886B2/en active Active
-
2018
- 2018-09-13 JP JP2018171042A patent/JP6530845B2/en active Active
-
2019
- 2019-05-17 JP JP2019093861A patent/JP2019151657A/en active Pending
-
2021
- 2021-04-19 JP JP2021070089A patent/JP2021152003A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019151657A5 (en) | ||
| JP2018197270A5 (en) | ||
| MX2022002952A (en) | Modified release formulations of 2-[3-[4-amino-3-(2-fluoro-4-phen oxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]- 4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile. | |
| JP2018158941A5 (en) | ||
| JP2009537538A5 (en) | ||
| JP2010132654A5 (en) | ||
| JP2015509519A5 (en) | ||
| JP2011207873A5 (en) | ||
| HRP20160880T4 (en) | Coated tablet formulation and method | |
| JP2018519302A5 (en) | ||
| JP2018515555A5 (en) | ||
| RS53570B1 (en) | Dpp iv inhibitor formulations | |
| JP2011503048A5 (en) | ||
| WO2019060322A3 (en) | High dosage valbenazine formulation and compositions, methods, and kits related thereto | |
| JP2008501025A5 (en) | ||
| JP2018526376A5 (en) | ||
| JP2020079283A5 (en) | ||
| CA2476587A1 (en) | Pharmaceutical formulation of iressa comprising a water-soluble cellulose derivative | |
| JP2011510024A5 (en) | ||
| WO2008129517A3 (en) | A stabilized delayed release pharmaceutical composition of rabeprazole | |
| JP2015511635A5 (en) | ||
| BR112018011376A2 (en) | pharmaceutical composition comprising a potent urat1 inhibitor | |
| AR100977A1 (en) | COMPOSITE FORMULATION FOR ORAL ADMINISTRATION INCLUDING EZETIMIBA AND ROSUVASTATIN, AND A PROCESS FOR PREPARATION | |
| JP2020532545A5 (en) | ||
| WO2010069795A3 (en) | Capecitabine rapidly disintegrating tablets |